Compare Wheaton Precious Metals Corp (WPM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wheaton Precious Metals Corp vs Zimmer Biomet Holdings Inc — how do they compare? Wheaton Precious Metals Corp trades at $138.54 (market cap $61.17B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Wheaton Precious Metals Corp is far larger — about 3.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Wheaton Precious Metals Corp for 66 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| WPM | ZBH | |
|---|---|---|
Market Cap | $61.17B | $16.95B |
Volume | 1,092,361 | 2,505,240 |
Sector | Basic Materials | Health |
52-Week High | $165.72 | $103.98 |
52-Week Low | $94.37 | $79.58 |
Typical Hold Time | 66 Days | 89 Days |
Enterprise Value | $63.05B | $24.02B |
Dividend Yield | 0.58% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wheaton Precious Metals (WPM) trades at $138.1, up 3.3% today, with a bearish technical signal despite recent earnings beats. The company reported record 2025 revenue of $2.31B and net income of $1.47B, supported by strong margins. Analyst consensus is bullish with an 80% buy rating and a $164.80 price target, while news highlights growth ambitions targeting 1.2M ounces by 2030.
WPM offers exposure to gold and silver streaming with robust profitability, but faces risks from gold price volatility and high valuations. The stock's upside hinges on execution of its funded growth pipeline, though technical indicators suggest near-term resistance near $138.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
